Wien (pta027/23.10.2019/13:00) - The Management Board of Sanochemia Pharmazeutika AG (ISIN AT0000776307, ISIN DE000A1G7JQ9) announces the conclusion of an asset deal of Alvetra & Werfft GmbH (SANOCHEMIA´s veterinary division) with Inovet / Belgium.
As a result, Inovet will be able to manufacture the products, market them internationally under its own name and expand them further through its own sales network.
SANOCHEMIA receives payments in form of milestones for the license transfer and royalties on future sales. The companies have agreed confidentiality on the amount of payments.
Inovet is a family-owned veterinary pharmaceutical company active worldwide, dedicated to research, production and marketing of veterinary pharmaceuticals and animal health products.
The activities are coordinated from the headquarters in Belgium, with a state-of-the-art production facility in the North of France and a commercial hub in Hungary.
Inovet offers over 160 different veterinary medicines and over 1,800 international marketing authorizations, under the umbrella of two leading veterinary brands: VMD® Livestock pharma and Biové® Laboratoires. (www.inovet.eu)
Moons Jan, CEO
|emitter:||SANOCHEMIA Pharmazeutika AG|
|contact person:||Bettina Zuccato|
|phone:||+43 1 3191456-336|
|stock exchanges:||free market in Dusseldorf, basic board in Frankfurt, free market in Hamburg, free market in Munich, free market in Stuttgart; direct market plus in Vienna; open market in Berlin|